All Updates

All Updates

icon
Filter
Earnings/results
Compass Pathways provides financial and business update for Q3 2022
Psychedelic Medicine
Nov 3, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Nov 3, 2022

Compass Pathways provides financial and business update for Q3 2022

Earnings/results

  • UK-based psychedelic drug developer Compass Pathways highlighted a few milestones in its Q3 financial results for the period ended September 30, 2022, which include publishing results of Phase II trials COMP360—Compass’ psilocybin therapy—for treatment-resistant depression (TRD) in a peer-reviewed journal and completed its long-term follow-up study, launching an investigator-led study for autism spectrum disorder in adults, and receiving ten patents to date.

  • Compass also outlined some targets for the upcoming quarters, which include launching the Phase III trial of COMP360 for TRD by December 2022, progressing in its ongoing Phase II trial of the candidate for anorexia nervosa and post-traumatic stress disorder (PTSD), and exploring other disease indications for COMP360. 

  • Compass reported a net loss per share of USD 0.43 in Q3 2022, beating analysts’ expectations by 12%. However, the firm’s net losses increased by 17% YoY to USD 18.4 million in Q3 2022 due to higher operating expenses.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.